Literature DB >> 8019583

Extension to the use of tolerance intervals for the assessment of individual bioequivalence.

J D Esinhart1, V M Chinchilli.   

Abstract

For the determination of bioequivalence, researchers have recently shifted their emphasis from average bioequivalence alone to average and individual bioequivalence. Existing methods for assessing average bioequivalence were first developed for the standard 2 x 2 crossover design, but these methods are easily generalized to the two-treatment, p-period crossover designs (e.g., TRR, RTT, and TTRR, RRTT, TRRT, RTTR). With respect to individual bioequivalence, Westlake (1,2) implemented the use of parametric and distribution-free tolerance intervals for assessing individual bioequivalence. Anderson and Hauck (3) described what they call the test of individual equivalence ratios (TIER) for the same purpose. Note that these methods have been applied and/or developed only for the standard 2 x 2 crossover design. The present work extends the method of using parametric tolerance intervals for assessing individual bioequivalence.

Mesh:

Year:  1994        PMID: 8019583     DOI: 10.1080/10543409408835071

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.

Authors:  R Schall; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

2.  Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.

Authors:  R N Patnaik; L J Lesko; M L Chen; R L Williams
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Measuring switchability and prescribability: when is average bioequivalence sufficient?

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

4.  Assessing individual equivalence in parallel group and crossover designs: Exact test and sample size procedures.

Authors:  Gwowen Shieh
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.